Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens Boots Alliance (WBA) concluded the recent trading session at $16.03, signifying a +0.5% move from its prior day's close.

Walgreens Boots Alliance (WBA) Advances But Underperforms Market: Key Facts

Investors are optimistic about Walgreens Boots (WBA), led by strategic alliances and new product launches.

Here's Why You Should Retain Walgreens Boots (WBA) For Now

Walgreens stock (NYSE: WBA) currently trades at $17 per share, about 70% below the level seen in April 2021, and it appears undervalued. WBA stock was trading at around $38 in early June 2022, just before the Fed started increasing rates, and is now 56% below that level, compared to 41% gains for the S&P 500 over this period.

How Does The Current Fall In Walgreens Stock Compare With The 2008 Crash?

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $400 million, which will be used for “debt paydown and general corporate purposes.”

Walgreens Sells Another Stake In Distributor Cencora For $400 Million

Cencora Inc

Cencora has agreed to buy about $400 million in stock back from Walgreens Boots Alliance, the second time the pharmacy chain has reduced its stake in the company this year as it looks to free up cash to pare down debt.

Cencora to buy $400 million in stock back from Walgreens

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) pursuant to a share repurchase by Cencora in the amount of approximately $400 million. With the transaction, Walgreens Boots Alliance's ownership of Cencora's common stock has decreased from approximately 13 percent to approximately 12 percent. Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate purpose.

Walgreens Boots Alliance Sells Shares of Cencora for $400 Million of Proceeds

Adobe

First American Financial

Freeport-McMoRan

Littelfuse

Marvell Technology

Micron Technology

NextEra Energy

SYNNEX

Vistra Energy

Hedge funds started cutting their stakes in the Magnificent Seven in the first quarter of 2024 and investing in broader artificial intelligence stocks instead, a new Goldman Sachs analysis shows.

Hedge funds cut stakes in Magnificent Seven to invest in broader AI boom

Pfizer

Dividend-paying stocks have more than doubled up the annualized average return of non-payers over the last half-century. Although roughly 80% of S&P 500 companies pay a regular dividend, only a little over a dozen sport a truly supercharged yield.

Time to Pounce: 2 Ultra-High-Yield S&P 500 Dividend Stocks That Are Screaming Buys Right Now

Recently, Zacks.com users have been paying close attention to Walgreens (WBA). This makes it worthwhile to examine what the stock has in store.

Walgreens Boots Alliance, Inc. (WBA) Is a Trending Stock: Facts to Know Before Betting on It

Billionaire money managers bought millions of shares of high-yield healthcare stocks during the first three months of 2024. John Overdeck and David Siegel of Two Sigma Investments bought over 8 million Pfizer shares, and they weren't the only billionaires interested in the pharmaceutical giant.

Billionaires Are Buying These High-Yield Dividend Stocks Left and Right. Should You Follow Their Lead?

Starbucks

Warner Bros Discovery Inc

Finding stable investment options is essential for investors looking to grow despite market volatility in today's unpredictable environment. Three companies emerge as strong contenders for a swift recovery.

Buy the Dip: 3 Growth Stocks Poised for a Rapid Rebound

Johnson & Johnson

Nuvei Corp

On 5/20/24, Nuvei, Walgreens Boots Alliance, and Johnson & Johnson will all trade ex-dividend for their respective upcoming dividends. Nuvei will pay its quarterly dividend of $0.10 on 6/6/24, Walgreens Boots Alliance will pay its quarterly dividend of $0.25 on 6/12/24, and Johnson & Johnson will pay its quarterly dividend of $1.24 on 6/4/24.

Ex-Dividend Reminder: Nuvei, Walgreens And Johnson & Johnson

Boeing

Intel

Walgreens Boots Alliance's problems go back years as it continues to post underwhelming top and bottom-line numbers. Boeing's quality control issues are serious as the company is losing the trust of customers, passengers, and investors.

Is Now the Time to Buy 3 of the S&P 500's Worst-Performing Stocks?

U.S. pharmacy chain operator Walgreens Boots Alliance said on Wednesday it has launched its own brand of popular overdose reversal drug, naloxone, which would be available over-the-counter (OTC).

Walgreens launches own brand of opioid overdose reversal drug

Walgreens saw its stock rise 5% on Monday, May 13, following the reports that it has contacted potential buyers for the Boots business. [1] Boots is a UK-based drugstore chain, and it could be valued at around $9 billion.

Is Walgreens Stock Undervalued At $18?

Walgreens said it will sell a two-dose pack of its naloxone for $34.99, around $10 cheaper than over-the-counter Narcan nasal spray.

Walgreens to offer its own cheaper version of opioid overdose reversal drug naloxone

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens today announced it is expanding access to an over the counter, life-saving medication with the launch of Walgreens Brand Naloxone HCI Nasal Spray. The product—which retails for $34.99, a lower price than the comparable national brand product at Walgreens stores, can reverse an overdose from opioids. The product is currently available online and will be chainwide in all stores by the end of the month, where it can be found in the pain aisle, providing.

Walgreens Brand Naloxone Available Online and In Stores This Month

Exxon Mobil

Blue-chip stocks to sell might seem odd, especially in a year with rising corporate earnings, a U.S. presidential election and possibly three rate cuts. However, stock investors must stay watchful, especially with the S&P 500 and Dow Jones Industrial Average up 10% and 4.7%, respectively, far from a bull run.

Blue-Chip Blues: 3 Stocks to Ditch Before They Drag You Down

DEERFIELD, Ill.--(BUSINESS WIRE)--To honor the service and sacrifices of Americans who served in the armed forces, Walgreens is offering a Memorial Day weekend discount to all veterans, active-duty military personnel and their immediate family members, including the families of those who lost their lives in service to their country. Beginning May 24 through May 27, customers with a myWalgreens® membership and valid military ID or proof of service will receive 20 percent off regularly priced pro.

Walgreens Honors Veterans, Active Duty Military and Their Families with Weekend Discount for Memorial Day Friday, May 24 through Monday, May 27

CVS Health

Adversity frequently presents chances for recovery and expansion in the stock market. Following recent market declines, three equities have emerged as strong candidates for recovery.

3 Beaten-Down Stocks Ready to Bounce Back Hard

A media report stated that the pharmacy-chain operator is in talks to sell a core asset. At one point, that business unit apparently could have fetched nearly $9 billion.

Why Walgreens Boots Alliance Stock Crushed the Market Today

Walgreens Boots Alliance (WBA) shares jumped in intraday trading Monday following a report that the big drugstore chain has been reaching out to potential buyers of its British-based Boots unit.

Walgreens Stock Jumps on Report It's Looking To Boot Boots

Walgreens Boots Alliance is once again attempting to sell its Boots pharmacies in the United Kingdom as the company chief executive officer Tim Wentworth and his new management team review the company's businesses.

Once Again, Walgreens May Try To Sell U.K. Boots Pharmacies

V.F.

Dividend Aristocrats are a unique class of dividend stocks. They are companies that are members of the S&P 500 and have increased their payouts to shareholders for at least 25 years.

Royalty No More: Time to Pounce or Flee From These 3 Stumbling Dividend Aristocrats?

The pharmacy giant is reaching out to possible buyers of its Boots drugstore chain in the United Kingdom, according to a report.

News for Walgreens Stock (WBA)